Successful rapid desensitization to intravenous bevacizumab using a 14-step protocol: Case report

Williams, Sharon Julie; Khokhar, Amrita; Gharib, Asal

doi:10.1016/j.jaip.2017.04.043

Cited by 8 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple protocols have been reported as single cases with few number of desensitizations for several ChD and mAb such as brentuximabvedotin [122,123], nivolumab [124], alemtuzumab [125,126], atezolizumab [127], bevacizumab [127,128], denosumab [129], daratumumab [130]and canakimumab [131]. Although this is not the scope of this article, considering the potential utility for the reader and the off-label use of some mAbs, a recent review of desensitization procedures performed with mAbs used in rheumatology has been reported [132].…”

Section: Rdd Protocols: Efficacy and Safety Immediate Reactionsmentioning

confidence: 99%

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

Vega¹,

Jiménez-Rodriguez²,

Barranco³

et al. 2021

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

Section: Rdd Protocols: Efficacy and Safety Immediate Reactionsmentioning

confidence: 99%

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

Vega¹,

Jiménez-Rodriguez²,

Barranco³

et al. 2021

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…There are different approaches for RDD in various centers, and the protocols are not fully standardized and harmonized for the BSs. There are many BSs (such as adalimumab, alemtuzumab, anakinra, bevacizumab, brentuximab, cetuximab, etanercept, infliximab, nivolumab, ofatumumab, panitumumab, rituximab, tocilizumab, and trastuzumab) in which RDD has been successfully applied, and new ones are added to the literature on a daily basis [40,[67][68][69][70][71][72][73][74][75]. An example for the 12-step RDD with rituximab is given in Tables 10 and 11 (for calculation see Ref.…”

Section: Desensitization Protocolsmentioning

confidence: 99%

Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches

2020

View full text Add to dashboard Cite

Purpose Biotechnological substances (BS) have rapidly expanded their clinical use. In parallel, there is an increase in expected or unexpected immunological or non-immunological adverse effects. In this part of the review, the current nomenclature of BSs, the classification of hypersensitivity reactions (HSR), as well as diagnostic and treatment approaches are documented to provide the tools to understand the nomenclature used throughout the databases and the need to harmonize it where applicable. Methods Detailed searches were performed on Pubmed, Web of Science, and Google Scholar to include all available publications. The search terms, such as specific BS, allergy, anaphylaxis, hypersensitivity, reactions, classification, diagnosis, grading, management, and desensitization, were determined for the search. Case reports, articles, and reviews on this subject were included. Results Today, a variety of non-standardized methods are used to support the clinical diagnosis. These include prick-to-prick tests and intradermal tests with the drug itself and its potentially allergenic ingredients. More rarely, anti-drug antibodies are detected and basophil activation tests are used by centers with research facilities. Although the treatment protocols for acute conditions vary, the overall approach is the same. Conclusion HSRs to BS are gradually increasing with the widening of their clinical use and indications. It is very important to prevent HSRs and to know the degree of severity as well as the emergency treatment algorithm. This review summarizes the diagnostic tests that should be applied: (a) immediately during/after a reaction, and (b) subsequently, and in the case that a switch of BS is not possible, desensitization is an option.

show abstract

Chemotherapy and Biologic Drug Allergy

Tam¹

2019

Allergy and Asthma

View full text Add to dashboard Cite

Successful rapid desensitization to intravenous bevacizumab using a 14-step protocol: Case report

Cited by 8 publications

References 5 publications

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches

Chemotherapy and Biologic Drug Allergy

Contact Info

Product

Resources

About